Apimeds and Lōkahi Secure FDA Meeting Confirmation for LT-100
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 11 2026
0mins
Source: Newsfilter
- FDA Meeting Confirmation: Apimeds Pharmaceuticals and Lōkahi Therapeutics announced that the FDA has confirmed a Type C meeting on May 4, 2026, to discuss the development of LT-100, a non-opioid biologic for osteoarthritis treatment, marking a significant step in their U.S. regulatory strategy.
- Product Background: LT-100, derived from pure honeybee venom, has a long history of clinical investigation and was initially approved for marketing in South Korea; the companies are now advancing its clinical progress in the U.S. by integrating historical data with rigorous development standards, showcasing its broad therapeutic potential.
- Manufacturing Enhancements: Currently, LT-100 is undergoing enhancements in its manufacturing process, with CEO Erik Emerson stating that updating the route of administration to align with current clinical best practices will reduce burdens for patients and providers, thereby positioning the program well for continued progress.
- Rigorous Development Plan: Lōkahi's SVP Susan Kramer emphasized that the team has thoroughly evaluated the nonclinical, clinical, and manufacturing components to ensure a cohesive and scientifically rigorous development plan, with early constructive engagement with the FDA being a critical step in responsibly advancing this asset.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
